This research details the creation of PMB@LNV-SyBV, a sophisticated hybrid nanovesicle designed to treat severe bacterial infections like pneumonia and sepsis. By fusing anti-inflammatory lemon-derived vesicles with detoxified synthetic bacterial vesicles, scientists developed a carrier that effectively encapsulates the antibiotic Polymyxin B. This platform utilizes a "neutrophil hitchhiking" strategy, where the body’s own immune cells recognize the vesicles and transport them directly to the site of infection. Once at the target, the vesicles release their cargo to eliminate carbapenem-resistant bacteria while simultaneously reducing harmful inflammation. Experimental results demonstrate that this method significantly improves survival rates and decreases bacterial loads in animal models. Ultimately, the study presents a biocompatible and scalable solution to overcome the toxicity and delivery limitations of traditional antibiotic treatments.

References:

• Li H, Yan H, Xiong J, et al. Neutrophil-mediated delivery of hybrid cross-species nanovesicles for treatment of bacterial infections[J]. Nature Communications, 2025.